# A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

> **NCT04241068** · PHASE3 · TERMINATED · sponsor: **Biogen** · enrollment: 1696 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Aducanumab

## Key facts

- **NCT ID:** NCT04241068
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-03-02
- **Primary completion:** 2024-07-22
- **Final completion:** 2024-07-22
- **Target enrollment:** 1696 (ACTUAL)
- **Why stopped:** Sponsor's Decision
- **Last updated:** 2025-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04241068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04241068, "A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04241068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*